Vas Narasimhan, Novartis CEO (Thibault Camus/AP Images, Pool)
December 5, 2022 01:46 PM ESTUpdated 02:21 PM
Pharma
FDA+

No­var­tis bol­sters Plu­vic­to's case in prostate can­cer with PhI­II re­sults

Nicole DeFeudis

Editor

The prog­no­sis is poor for metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer (mCR­PC) pa­tients. No­var­tis wants to change that by mak­ing its re­cent­ly ap­proved Plu­vic­to avail­able to pa­tients …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Bio­gen makes cuts across its re­search unit, shift­ing fo­cus to ‘ex­ter­nal op­por­tu­ni­ties’

Bio­Marin turns to ex-Roche deal­mak­er James Sabry to build ‘next ver­sion’ of 27-year-old com­pa­ny

An­thos' de­tailed mid-stage da­ta back its an­ti­co­ag­u­lant, but can the drug suc­ceed where Bay­er's failed?

Chi­na's biotech boom is threat­en­ing US drug­mak­er­s' dom­i­nance

Te­va’s MS drug and gener­ics to add black box warn­ing for ana­phy­lax­is

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times